TVD 2016

Treatment volume adaptation

Goal: decreased NTCP, increased TCP by increased dose

I Tumor regression 0.6%-2.4% per day, high regression results in poor outcome (in non-adenocarcinoma histology) I Noticeable tumor regression in 40% of patients (progression in only 1%), which was >25% in 17% of the patients in the fourth week (N=114) I Tumor shrinkage more pronounced in concurrent as opposed to sequential RCHT (50.1% versus 33.7%, respectively, p =0.003) I Treatment planning studies investigating dose escalation resulted in varying results

Sonke, Belderbos. Sem Radiat Oncol 2011 Brink, et al ., Radiother Oncol 2014 Zwienen, et al . Int J Radiat Oncol Biol Phys 2008 Berkovic, et al . Acta Oncol 2015

www.uniklinikum-dresden.de